Philogen
Clinical-stage biotechnology company developing antibody-based medicines that target disease-associated blood vessels.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Melanoma Stage IIIB
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaPhase 1 · Recruiting · Glioblastoma
Safety and Early Signs of Efficacy of IL12-L19L19.Phase 1 · Recruiting · Advanced Solid Tumor
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate CancerPhase 1 · Recruiting · Prostate Cancer
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid TumorsPhase 1 · Recruiting · FAP
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsPhase 2 · Recruiting · Melanoma Stage III
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/philogen/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.